Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Dynamics of seroconversion of anti-SARS-CoV-2 IgG antibodies in the Czech unvaccinated population: nationwide prospective seroconversion (PROSECO) study

View ORCID ProfilePavel Piler, View ORCID ProfileVojtěch Thon, Lenka Andrýsková, Kamil Doležel, David Kostka, Tomáš Pavlík, Ladislav Dušek, Hynek Pikhart, Martin Bobák, Srdan Matic, Jana Klánová
doi: https://doi.org/10.1101/2021.08.15.21262007
Pavel Piler
1RECETOX Centre, Faculty of Science, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pavel Piler
Vojtěch Thon
1RECETOX Centre, Faculty of Science, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vojtěch Thon
  • For correspondence: vojtech.thon@recetox.muni.cz
Lenka Andrýsková
1RECETOX Centre, Faculty of Science, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kamil Doležel
2QualityLab Association, Evropská 846/176a, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Kostka
3Health Insurance Company of the Ministry of the Interior of the Czech Republic, Vinohradská 2577/178, 130 00, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomáš Pavlík
4Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 3, 625 00, Brno, Czech Republic
5Institute of Health Information and Statistics of the Czech Republic, Palackého náměstí 4, 128 01, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ladislav Dušek
4Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 3, 625 00, Brno, Czech Republic
5Institute of Health Information and Statistics of the Czech Republic, Palackého náměstí 4, 128 01, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hynek Pikhart
1RECETOX Centre, Faculty of Science, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic
6Department of Epidemiology & Public Health, University College London, 1 – 19 Torrington Place, London WC1E 6BT, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Bobák
1RECETOX Centre, Faculty of Science, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic
6Department of Epidemiology & Public Health, University College London, 1 – 19 Torrington Place, London WC1E 6BT, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Srdan Matic
7World Health Organization (WHO), Country Office in the Czech Republic, Rytířská 31, 110 00, Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jana Klánová
1RECETOX Centre, Faculty of Science, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Although the Czech Republic weathered the first wave of the COVID-19 epidemic with relatively low incidence, the second wave of the global pandemic saw it rank among countries bearing the greatest COVID-19 burden, both in Europe and on a worldwide scale. The aim of the nationwide prospective seroconversion (PROSECO) study was to investigate the dynamics of seroconversion of anti-SARS-CoV-2 IgG antibodies in the Czech population.

Methods All clients of the second largest health insurance company in the Czech Republic were sent a written invitation to participate in this longitudinal study. The study includes the first 30,054 persons who provided a blood sample between October 2020 and March 2021. Seroprevalence was compared between calendar periods of blood sample collection, RT-PCR test results, sociodemographic factors, and other characteristics.

Findings The data show a dramatic increase in seropositivity over time, from 28% in October/November 2020 to 43% in December 2020/January 2021 to 51% in February/March 2021. These trends were consistent with government data on cumulative viral antigenic prevalence in the population captured by PCR testing – although the seroprevalence rates established in this study were considerably higher than those listed in government data. Data pooled across the entire study period exhibited minor differences in seropositivity between sexes, age groups and body mass index categories; results were similar between test providing laboratories. Seropositivity was substantially higher among symptomatic vs. asymptomatic persons (76% vs. 34%). At least one third of all seropositive participants were asymptomatic, and 28% participants who developed antibodies against SARS-CoV-2 never underwent PCR testing.

Interpretation Antibody response provides a better marker of past SARS-CoV-2 infection than PCR testing data. Our data on seroconversion confirm the rapidly increasing prevalence in the Czech population during the dramatically rising pandemic wave prior to the beginning of massive vaccination. The planned second and third assessment of the study participants (April 2021 – September 2021, October 2021 – March 2022) will provide valuable evidence on the seroprevalence changes following vaccination and persistence of antibodies resulting from natural infection and vaccination.

Evidence before this study Similarly to most European countries, the first COVID-19 epidemic wave in the Czech Republic produced a relatively low incidence (86.9 confirmed cases per 100,000 persons over three months). At the peaks of the second wave, however, over 100 confirmed cases per 100,000 persons were diagnosed daily and the Czech Republic ranked among the countries with the greatest burden of COVID-19 in Europe and in the world. Only a few nationwide population-based studies have been published covering the second wave of the epidemic in Europe, and none of them from the Central and Eastern European region.

Added value of this study The PROSECO study will provide key data from the heavily affected Central European region and contribute to the epidemiological and serological characteristics of the SARS-CoV-2 infection. All 30,054 study participants were recruited between October 2020 and March 2021, thus covering all three epidemic peaks (November 2020, January and March 2021) of the second COVID-19 epidemic wave. This allows us to follow the dynamics of seroconversion of anti-SARS-CoV-2 IgG antibodies in the immunologically naive and unvaccinated population during the COVID-19 pandemic. The study participants will be re-assessed in the second (April 2021 – September 2021) and third (October 2021 – March 2022) PROSECO phases to further study the post-infection/post-vaccination dynamics of seroconversion in/after a period of massive vaccination.

Implications of all the available evidence Data from the first phase of the PROSECO study indicate that the percentage of the population that has been exposed to the SARS-CoV-2 may be substantially higher than estimates based on official data on cumulative viral positivity incidence as at least one third of seropositive participants were asymptomatic, and 28% of participants who developed antibodies against SARS-CoV-2 never underwent PCR testing. Regional seroprevalence data provide key information to inform, in combination with other surveillance data, public health policies and will be instrumental for the successful management of the subsequent phases of the global pandemic.

The number of seropositive participants who never underwent RT-PCR testing demonstrates the importance of serological population-based studies describing the spread and exposure to the virus in the population over time.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The Health Insurance Company of the Ministry of the Interior of the Czech Republic, as the main study sponsor, collaborated on the design of the study and commented on the drafted manuscript but it had no role in data collection, data analysis, data interpretation, or writing of the report. Other funders (MEYS, EU H2020, ESIF) had no role in the study design, sample and data collection, data analysis and interpretation, or writing of the manuscript. PP, VT, TP, LD, HP, MB and JK had access to all study data and PP and VT were responsible for the final manuscript submission.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

ELSPAC (European Longitudinal Study Parents and Children) ethics committee under reference number (C)ELSPAC/EK/5/2021

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

no available data

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted August 18, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Dynamics of seroconversion of anti-SARS-CoV-2 IgG antibodies in the Czech unvaccinated population: nationwide prospective seroconversion (PROSECO) study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Dynamics of seroconversion of anti-SARS-CoV-2 IgG antibodies in the Czech unvaccinated population: nationwide prospective seroconversion (PROSECO) study
Pavel Piler, Vojtěch Thon, Lenka Andrýsková, Kamil Doležel, David Kostka, Tomáš Pavlík, Ladislav Dušek, Hynek Pikhart, Martin Bobák, Srdan Matic, Jana Klánová
medRxiv 2021.08.15.21262007; doi: https://doi.org/10.1101/2021.08.15.21262007
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Dynamics of seroconversion of anti-SARS-CoV-2 IgG antibodies in the Czech unvaccinated population: nationwide prospective seroconversion (PROSECO) study
Pavel Piler, Vojtěch Thon, Lenka Andrýsková, Kamil Doležel, David Kostka, Tomáš Pavlík, Ladislav Dušek, Hynek Pikhart, Martin Bobák, Srdan Matic, Jana Klánová
medRxiv 2021.08.15.21262007; doi: https://doi.org/10.1101/2021.08.15.21262007

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (579)
  • Anesthesia (140)
  • Cardiovascular Medicine (1947)
  • Dentistry and Oral Medicine (252)
  • Dermatology (185)
  • Emergency Medicine (333)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (700)
  • Epidemiology (11108)
  • Forensic Medicine (8)
  • Gastroenterology (626)
  • Genetic and Genomic Medicine (3182)
  • Geriatric Medicine (309)
  • Health Economics (563)
  • Health Informatics (2043)
  • Health Policy (863)
  • Health Systems and Quality Improvement (782)
  • Hematology (310)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12729)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (336)
  • Neurology (2993)
  • Nursing (164)
  • Nutrition (465)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1556)
  • Ophthalmology (478)
  • Orthopedics (185)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (403)
  • Pediatrics (914)
  • Pharmacology and Therapeutics (382)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2789)
  • Public and Global Health (5597)
  • Radiology and Imaging (1095)
  • Rehabilitation Medicine and Physical Therapy (635)
  • Respiratory Medicine (761)
  • Rheumatology (339)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (289)
  • Surgery (343)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (133)